Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03981705 · ClinicalTrials.gov registry record
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
A clinical trial, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- 8
- Enrollment target
NCT03981705: Completed study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT03981705 is a clinical trial that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03981705 has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.
Primary Outcome
The primary aim of this feasibility study is to determine whether breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC) can accurately predict complete pathologic response (pCR) in women with biopsyproven triple negative or HER2+ breast cancer.
Interventions
- RADIATION Standard Trimodality Breast Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-08-08 |
| Est. Completion | 2024-11-26 |
What the finished NCT03981705 record still lists
NCT03981705 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Standard Trimodality Breast Imaging is the first listed.
NCT03981705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03981705 about?
NCT03981705 is a clinical study titled "Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer". This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast c...
What is the current status of trial NCT03981705?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2019-08-08. Estimated completion is 2024-11-26.
What interventions are being tested in trial NCT03981705?
The interventions under investigation include: Standard Trimodality Breast Imaging (RADIATION).
Who is sponsoring clinical trial NCT03981705?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI